Ser461

Site Information
PkFsIGDsPDsStPK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4763255
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 )
Disease tissue studied:	breast cancer ( 3 , 4 , 8 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 3 ) , leukemia ( 11 ) , acute myelogenous leukemia ( 11 ) , lung cancer ( 5 , 8 ) , non-small cell lung cancer ( 8 ) , small-cell lung cancer ( 5 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 18 ) , 293 (epithelial) ( 12 , 13 , 14 , 15 , 16 , 17 ) , breast ( 1 , 3 ) , BT-549 (breast cell) ( 8 ) , Calu 6 (pulmonary) ( 8 ) , DMS79 (pulmonary) ( 5 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 9 ) , H2009 (pulmonary) ( 8 ) , H2077 (pulmonary) ( 8 ) , H2887 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC2279 (pulmonary) ( 8 ) , HCC366 (pulmonary) ( 8 ) , HCC78 (pulmonary) ( 8 ) , HCC827 (pulmonary) ( 8 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 4 ) , HMLER ('stem, breast cancer') ( 4 ) , Jurkat (T lymphocyte) ( 6 ) , K562 (erythroid) ( 7 ) , KG-1 (myeloid) ( 11 ) , LCLC-103H (pulmonary) ( 8 ) , LOU-NH91 (squamous) ( 8 ) , lung ( 5 ) , MDA-MB-231 (breast cell) ( 8 ) , NCI-H128 (pulmonary) ( 5 ) , NCI-H1395 (pulmonary) ( 8 ) , NCI-H1417 (pulmonary) ( 5 ) , NCI-H1648 (pulmonary) ( 8 ) , NCI-H2030 (pulmonary) ( 8 ) , NCI-H209 (pulmonary) ( 5 ) , NCI-H2172 (pulmonary) ( 8 ) , NCI-H460 (pulmonary) ( 8 ) , NCI-H524 (pulmonary) ( 5 ) , WM239A (melanocyte) ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
7	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
8	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
9	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
10	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
11	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
12	Guo A (2010) CST Curation Set: 9972; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
13	Guo A (2010) CST Curation Set: 9968; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
14	Guo A (2010) CST Curation Set: 9970; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
15	Guo A (2010) CST Curation Set: 9969; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
16	Guo A (2010) CST Curation Set: 9973; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
17	Guo A (2010) CST Curation Set: 9971; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
18	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info